Skip to main content

Commentary: recombinant activated factor VII: the controversial conundrum regarding its off-label use.

Publication ,  Other
Karkouti, K; Levy, JH
Published in: Anesth Analg
October 2011

Duke Scholars

Published In

Anesth Analg

DOI

EISSN

1526-7598

Publication Date

October 2011

Volume

113

Issue

4

Start / End Page

711 / 712

Location

United States

Related Subject Headings

  • Ticlopidine
  • Recombinant Proteins
  • Platelet Aggregation Inhibitors
  • Male
  • Humans
  • Hemostatics
  • Hemostasis
  • Hemorrhage
  • Factor VIIa
  • Clopidogrel
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Karkouti, K., & Levy, J. H. (2011). Commentary: recombinant activated factor VII: the controversial conundrum regarding its off-label use. Anesth Analg. United States. https://doi.org/10.1213/ANE.0b013e318228c6a9
Karkouti, Keyvan, and Jerrold H. Levy. “Commentary: recombinant activated factor VII: the controversial conundrum regarding its off-label use.Anesth Analg, October 2011. https://doi.org/10.1213/ANE.0b013e318228c6a9.
Karkouti, Keyvan, and Jerrold H. Levy. “Commentary: recombinant activated factor VII: the controversial conundrum regarding its off-label use.Anesth Analg, vol. 113, no. 4, Oct. 2011, pp. 711–12. Pubmed, doi:10.1213/ANE.0b013e318228c6a9.

Published In

Anesth Analg

DOI

EISSN

1526-7598

Publication Date

October 2011

Volume

113

Issue

4

Start / End Page

711 / 712

Location

United States

Related Subject Headings

  • Ticlopidine
  • Recombinant Proteins
  • Platelet Aggregation Inhibitors
  • Male
  • Humans
  • Hemostatics
  • Hemostasis
  • Hemorrhage
  • Factor VIIa
  • Clopidogrel